DE69110625T2 - Oxazolopyridinderivate, Verfahren zu ihrer Herstellung und die sie enthaltenden pharmazeutischen Zusammensetzungen. - Google Patents

Oxazolopyridinderivate, Verfahren zu ihrer Herstellung und die sie enthaltenden pharmazeutischen Zusammensetzungen.

Info

Publication number
DE69110625T2
DE69110625T2 DE69110625T DE69110625T DE69110625T2 DE 69110625 T2 DE69110625 T2 DE 69110625T2 DE 69110625 T DE69110625 T DE 69110625T DE 69110625 T DE69110625 T DE 69110625T DE 69110625 T2 DE69110625 T2 DE 69110625T2
Authority
DE
Germany
Prior art keywords
processes
preparation
pharmaceutical compositions
compositions containing
oxazolopyridine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69110625T
Other languages
English (en)
Other versions
DE69110625D1 (de
Inventor
Gerald Guillaumet
Christine Flouzat
Michelle Devissaguet
Pierre Renard
Daniel Henri Caignard
Gerard Adam
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ADIR SARL
Original Assignee
ADIR SARL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ADIR SARL filed Critical ADIR SARL
Application granted granted Critical
Publication of DE69110625D1 publication Critical patent/DE69110625D1/de
Publication of DE69110625T2 publication Critical patent/DE69110625T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
DE69110625T 1990-11-20 1991-11-20 Oxazolopyridinderivate, Verfahren zu ihrer Herstellung und die sie enthaltenden pharmazeutischen Zusammensetzungen. Expired - Fee Related DE69110625T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9014381A FR2669336B1 (fr) 1990-11-20 1990-11-20 Nouveaux derives d'oxazolo pyridines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.

Publications (2)

Publication Number Publication Date
DE69110625D1 DE69110625D1 (de) 1995-07-27
DE69110625T2 true DE69110625T2 (de) 1996-02-22

Family

ID=9402340

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69110625T Expired - Fee Related DE69110625T2 (de) 1990-11-20 1991-11-20 Oxazolopyridinderivate, Verfahren zu ihrer Herstellung und die sie enthaltenden pharmazeutischen Zusammensetzungen.

Country Status (12)

Country Link
US (1) US5130311A (de)
EP (1) EP0487408B1 (de)
JP (1) JPH0735371B2 (de)
AT (1) ATE124047T1 (de)
AU (1) AU640289B2 (de)
CA (1) CA2055859A1 (de)
DE (1) DE69110625T2 (de)
FR (1) FR2669336B1 (de)
IE (1) IE914012A1 (de)
NZ (1) NZ240656A (de)
PT (1) PT99557A (de)
ZA (1) ZA919181B (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2663929A1 (fr) * 1990-06-29 1992-01-03 Adir Nouveaux derives d'oxazolo pyridines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5618819A (en) * 1994-07-07 1997-04-08 Adir Et Compagnie 1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one and oxazolo[4,5-b]pyridin-2-(3H)-one compounds
PT1685839E (pt) 1997-12-22 2013-07-08 Euro Celtique Sa Forma de dosagem farmacêutica por via oral compreendendo uma combinação de um agonista opióide e de um antagonista opióide
CA2314896C (en) * 1997-12-22 2005-09-13 Euro-Celtique, S.A. A method of preventing abuse of opioid dosage forms
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
EP1935421A1 (de) 2000-02-08 2008-06-25 Euro-Celtique S.A. Kontrolliert freigesetzte Zusammensetzungen mit einem Opioid-Agonisten und einem Opioid-Antagonisten
HUP0204163A2 (hu) 2000-02-08 2003-04-28 Euro-Celtique S.A. Opioid agonistát és antagonistát tartalmazó szabályozott leadású készítmény és eljárás az előállítására
UA81224C2 (uk) 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
US20030065002A1 (en) 2001-05-11 2003-04-03 Endo Pharmaceuticals, Inc. Abuse-resistant controlled-release opioid dosage form
PT1416842E (pt) 2001-07-18 2009-03-31 Euro Celtique Sa Composições farmacêuticas de oxicodona e naloxona
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US20030157168A1 (en) 2001-08-06 2003-08-21 Christopher Breder Sequestered antagonist formulations
PL367427A1 (en) 2001-08-06 2005-02-21 Euro-Celtique S.A. Opioid agonist formulations with releasable and sequestered antagonist
SI2425824T1 (sl) 2002-04-05 2017-06-30 Mundipharma Medical Cee Gmbh Farmacevtski pripravek, ki vsebuje oksikodon in nalokson
HUE038446T2 (hu) 2002-09-20 2018-10-29 Alpharma Pharmaceuticals Llc Szekvesztráló alegység és releváns kompozíciók és módszerek
WO2004032870A2 (en) * 2002-10-08 2004-04-22 Rinat Neuroscience Corp. Methods for treating post-surgical pain by admisnistering a nerve growth factor antagonist and compositions containing the same
UA80447C2 (en) * 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
AU2003304238A1 (en) 2002-10-08 2005-01-13 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same
ES2382918T3 (es) 2002-12-24 2012-06-14 Rinat Neuroscience Corp. Anticuerpos anti-NGF y procedimientos que usan los mismos
US9498530B2 (en) 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
US7569364B2 (en) * 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
EP1594441B1 (de) 2003-02-19 2010-12-15 Rinat Neuroscience Corp. Verfahren zur behandlung von schmerzen durch verabreichung eines nervenwachstumsfaktor-antagonisten und eines nsaid und diese enthaltende zusammensetzung
TWI347201B (en) 2003-04-21 2011-08-21 Euro Celtique Sa Pharmaceutical products,uses thereof and methods for preparing the same
EP2298303A1 (de) 2003-09-25 2011-03-23 Euro-Celtique S.A. Pharmazeutische kombinationen von hydrocodon und naltrexon
CA2562024C (en) * 2004-04-07 2014-05-27 Rinat Neuroscience Corp. Methods for treating bone cancer pain by administering a nerve growth factor antagonist
EP1604666A1 (de) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioide zur Behandlung der chronischen obstruktiven Lungenkrankheit
EP3326617A1 (de) 2004-06-12 2018-05-30 Collegium Pharmaceutical, Inc. Missbrauchsverhindernde arzneimittelformulierungen
CA2570048A1 (en) * 2004-07-07 2006-01-12 Medicure International Inc. Combination therapies employing platelet aggregation drugs
US7459468B2 (en) * 2004-10-28 2008-12-02 Medicure International, Inc. Aryl sulfonic pyridoxines as antiplatelet agents
US20060094749A1 (en) * 2004-10-28 2006-05-04 Medicure International Inc. Substituted pyridoxines as anti-platelet agents
US7812037B2 (en) 2004-10-28 2010-10-12 Medicure International, Inc. Dual antiplatelet/anticoagulant pyridoxine analogs
EP1702558A1 (de) * 2005-02-28 2006-09-20 Euro-Celtique S.A. Verfahren und Vorrichtung zur Darmtätigkeitserfassung
EP2484346B1 (de) 2006-06-19 2017-02-22 Alpharma Pharmaceuticals LLC Pharmazeutische Zusammensetzungen
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
US20100160351A1 (en) * 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
WO2010071865A1 (en) 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
PL2405915T3 (pl) 2009-03-10 2019-05-31 Euro Celtique Sa Kompozycje farmaceutyczne o natychmiastowym uwalnianiu zawierające oksykodon i nalokson
WO2011032175A1 (en) 2009-09-14 2011-03-17 Nuon Therapeutics, Inc. Combination formulations of tranilast and allopurinol and methods related thereto
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
HUE058226T2 (hu) 2010-08-19 2022-07-28 Zoetis Belgium S A NGF elleni antitestek és alkalmazásuk
EP2826468A1 (de) 2010-12-22 2015-01-21 Purdue Pharma L.P. Gekapselte manipulationssichere Darreichungsformen mit gesteuerter Freisetzung
CN103327969A (zh) 2010-12-23 2013-09-25 普渡制药公司 抗篡改固体口服剂型
TR201904088T4 (tr) 2011-05-20 2019-05-21 Alderbio Holdings Llc Anti-CGRP bileşimleri ve bunların kullanımları.
CN104364264B (zh) 2012-06-06 2018-07-24 硕腾服务有限责任公司 犬源化抗ngf抗体和其方法
KR101840526B1 (ko) 2013-02-05 2018-03-20 퍼듀 퍼머 엘피 내변조성 제약 제제
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
KR20180037074A (ko) 2013-07-23 2018-04-10 유로-셀티큐 에스.에이. 장내 세균총이상을 초래하고/하거나 장내 박테리아 전위에 대한 위험을 증가시키는 질환과 통증으로 인해 고통받고 있는 환자에서 통증을 치료하는데 사용하기 위한 옥시코돈과 날록손의 조합물
SG10202109689QA (en) 2016-04-15 2021-10-28 Alder Biopharmaceuticals Inc Humanized anti-pacap antibodies and uses thereof
WO2017222575A1 (en) 2016-06-23 2017-12-28 Collegium Pharmaceutical, Inc. Process of making more stable abuse-deterrent oral formulations
US10982002B2 (en) 2018-03-12 2021-04-20 Zoetis Services Llc Anti-NGF antibodies and methods thereof
CA3229059A1 (en) 2021-08-27 2023-03-02 H. Lundbeck A/S Treatment of cluster headache using anti-cgrp antibodies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3929809A (en) * 1970-06-26 1975-12-30 Ciba Geigy Corp Oxazolo-{8 4,5-b{9 -pyridine-2-ones and -2-thiones as intermediates
GB8601160D0 (en) * 1986-01-17 1986-02-19 Fujisawa Pharmaceutical Co Heterocyclic compounds
FR2650591B1 (fr) * 1989-08-07 1991-11-15 Science Organisation Nouveaux derives d'oxazolo pyridines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
IE912063A1 (en) * 1990-06-18 1991-12-18 Merck & Co Inc Inhibitors of hiv reverse transcriptase
IL98526A0 (en) * 1990-06-18 1992-07-15 Merck & Co Inc Pyridones,processes for their preparation and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
JPH0735371B2 (ja) 1995-04-19
EP0487408B1 (de) 1995-06-21
ATE124047T1 (de) 1995-07-15
CA2055859A1 (fr) 1992-05-21
EP0487408A1 (de) 1992-05-27
US5130311A (en) 1992-07-14
FR2669336A1 (fr) 1992-05-22
AU640289B2 (en) 1993-08-19
JPH04283566A (ja) 1992-10-08
NZ240656A (en) 1992-11-25
FR2669336B1 (fr) 1993-01-22
PT99557A (pt) 1992-10-30
IE914012A1 (en) 1992-05-20
DE69110625D1 (de) 1995-07-27
ZA919181B (en) 1992-08-26
AU8794291A (en) 1992-05-21

Similar Documents

Publication Publication Date Title
DE69110625D1 (de) Oxazolopyridinderivate, Verfahren zu ihrer Herstellung und die sie enthaltenden pharmazeutischen Zusammensetzungen.
ATE128458T1 (de) Naphtylalkylamine, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen.
ATE40368T1 (de) Xanthin-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen.
DE69415373D1 (de) Pyridothiadiazine, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Zusammensetzungen
ZA936658B (en) Benzopyran compounds process for their preparation and the pharmaceutical compositions which contain them
ATE100464T1 (de) Peptid-derivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
ATE145899T1 (de) Trimetazidinederivate, verfahren zu deren herstellung und deren pharmazeutischen zusammensetzungen
ATE152707T1 (de) Neue naphthalin-amide und sulfonamide, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zusammensetzungen
ATE193531T1 (de) Phenyl-carboxamide-isoxazole-derivate und salze, verfahren zu ihrer herstellung ihre anwendung als arzneimittel und pharmazeutische zusammensetzungen die sie enthalten
ATE172976T1 (de) 3-aminochroman-spiroderivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen
ATE214051T1 (de) Substituierte tetrahydropyridinderivate, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
DE69300296T2 (de) Thiochromanderivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen.
AU639154B2 (en) New imidazole compounds, a process for the preparation thereof, and pharmaceutical compositions containing them
DE69300197T2 (de) Aminoalkylchromone, Verfahren zu ihrer Herstellung und diese enthaltende Zusammensetzungen.
DE69400283D1 (de) (Cyclohexyl)alkenderivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammensetzungen
DE69403606T2 (de) Cyclizierte Analoge der Fettsäurenmetaboliten, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen
ATE82289T1 (de) 1-hydroxyalkylxanthine, verfahren zu ihrer herstellung und sie enthaltende medikamente.
ZA933942B (en) Pyrrolothienopyrazine compounds, processes for the preparation thereof and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee